Regeneron Pharmaceuticals (REGN) has been involved in numerous recent buy and sell transactions. Flower City Capital took a $262,000 position and Eaton Financial Holdings made a $494,000 investment. In contrast, Perigon Wealth Management sold 1,432 shares, and Public Employees Retirement System of Ohio sold 949. Regeneron suffered a court setback regarding EYLEA, leading to speculation about its valuation. Notwithstanding, its R&D pipeline is considered robust with positive growth prospects. Regulatory uncertainty also looms large. JPMorgan trimmed REGN's price target, calling the sell-off excessive. REGN released the results for EMPOWER-Lung 3 trial and gained an FDA label expansion for Evkeeza, with encouraging results from two phase 3 trials exploring first-in-class allergy antibody-blockers. The FDA extended review deadlines for two of REGN's submissions. Despite the stock being down by 51% from all-time highs, various firms still maintain a 'buy' rating on it. Most notably, REGN saw large growth in short interest. REGN now holds $256M worth of 23andMe assets and received approval for Dupixent® by US FDA. Most recent is the success of its rare bone disorder drug in late-stage trials, which could trigger a major comeback.
Regeneron Pharmaceuticals REGN News Analytics from Wed, 07 May 2025 07:00:00 GMT to Sat, 27 Sep 2025 20:44:36 GMT -
Rating 2
- Innovation 6
- Information 8
- Rumor -1
